Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
115.00
-0.50 (-0.43%)
Jun 5, 2026, 1:30 PM CST
Market Cap19.26B -27.3%
Revenue (ttm)31.42M -27.9%
Net Income-356.04M
EPS-2.14
Shares Out 167.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume334,819
Open116.00
Previous Close115.50
Day's Range112.00 - 117.00
52-Week Range112.50 - 329.50
Beta0.22
Analystsn/a
Price Targetn/a
Earnings DateAug 7, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors. In addition, the compa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 39
Stock Exchange Taipei Exchange
Ticker Symbol 6535
Full Company Profile

Financial Performance

In 2025, Lumosa Therapeutics's revenue was 35.83 million, a decrease of -8.49% compared to the previous year's 39.15 million. Losses were -340.54 million, -19.83% less than in 2024.

Financial Statements